Latest news with #AsiaPacific
Yahoo
2 minutes ago
- Business
- Yahoo
Raymond James Raises PT on Methanex Corporation (MEOH) from $40 to $45; Maintains ‘Outperform' Rating
Methanex Corporation (NASDAQ:MEOH) is included in our list of the . A vast oil and gas rig silhouetted in the sunset, capturing the power of Swift Energy Company. On July 15, 2025, Raymond James increased its price target on Methanex Corporation (NASDAQ:MEOH) to $45.00 from $40.00, maintaining an 'Outperform' rating. The analyst aligned its target with broader analyst sentiment. Due to long-lasting supply concerns in major methanol-producing regions, particularly Iran, methanol prices have been doing better, driving positive market sentiment. Both spot and contract prices have benefited from the global supply disruptions. Looking ahead, Raymond James raised its 2025 and 2026 earnings estimates for Methanex Corporation (NASDAQ:MEOH), reflecting the favorable pricing environment. Furthermore, its acquisition of OCI Global's international methanol business positions the company for continued growth. Methanex Corporation (NASDAQ:MEOH) is a methanol producer, operating in Asia-Pacific, North America, Europe, and South America. It remains on our list of the most undervalued stocks. While we acknowledge the potential of MEOH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 14 Cheap Transportation Stocks to Buy According to Analysts and 10 Cheap Lithium Stocks to Buy According to Hedge Funds. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Business
- Yahoo
Wyndham to expand network with addition of five Ovolo hotels
Wyndham Hotels & Resorts has forged an alliance with lifestyle hotel pioneer Ovolo Group. This collaboration will add five Ovolo hotels in Australia and Hong Kong to the Wyndham brand later in the year. The agreement allows Ovolo Group to retain ownership and management of their properties while leveraging Wyndham's network to expand development opportunities across the Asia Pacific region. More than 450 rooms from existing Ovolo hotels in Sydney, Brisbane, Canberra, Melbourne, and Hong Kong are slated to integrate into Wyndham's portfolio. Ovolo Group chief of staff Shivang Jhunjhnuwala said: 'Ovolo isn't just a hotel brand, it's a lifestyle, a creative force that fuses fashion, art, music and entertainment. Since 2010, we've built a bold, culture-led brand that disrupts the cookie-cutter hotel experience. 'Now, through our partnership with Wyndham, we're flipping the script to unlock bold new growth opportunities by franchising a lifestyle brand without diluting its DNA. Wyndham is a global leader in hotel franchising—with the scale, infrastructure, and expertise to help us grow with intention and impact. Just as importantly, Ovolo brings something different—an edge and energy that complements Wyndham's presence in the upscale lifestyle market.' Wyndham Hotels & Resorts Asia Pacific president Joon Aun OOI said: 'This partnership marks a significant milestone for Wyndham, further expanding our upscale presence in the Asia Pacific region by combining Ovolo's strengths in the lifestyle segment with our extensive global network. The future of travel isn't about sameness—it's about spaces with soul, brands with a point of view and experiences that don't blur into the background.' These five properties will benefit from access to sales, marketing and distribution platforms provided by Wyndham, extending their reach and creating new commercial prospects. Additionally, these five hotels will become part of the Wyndham Rewards loyalty programme. "Wyndham to expand network with addition of five Ovolo hotels" was originally created and published by Hotel Management Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Business
- Yahoo
Smart IR Heating Systems Gain Traction in Precision Applications
By 2034, the Global Infrared Quartz Lamp Market is set to grow from USD 1.31 Billion in 2025 to USD 2.19 Billion, driven by a 7.6% CAGR. Key sectors—automotive, packaging, and more—benefit from energy-efficient, quick-response heating. Asia-Pacific sees significant growth. Explore trends, segmentation, and market forecasts. Infrared Quartz Lamp Market Dublin, July 30, 2025 (GLOBE NEWSWIRE) -- The "Infrared Quartz Lamp Market Size, Share, Trends, Analysis, and Forecast 2025-2034 | Global Industry Growth, Competitive Landscape, Opportunities, and Challenges" report has been added to Global Infrared Quartz Lamp Market Size is valued at USD 1.31 Billion in 2025. Worldwide sales of Infrared Quartz Lamp Market are expected to grow at a significant CAGR of 7.6%, reaching USD 2.19 Billion by the end of the forecast period in 2034. The Infrared Quartz Lamp Market is witnessing steady growth driven by its widespread application across industrial, commercial, and residential settings. Infrared quartz lamps are valued for their efficient and targeted heat transfer, fast response time, and energy-saving potential. These lamps emit infrared radiation that is absorbed directly by objects without significantly heating the surrounding air, making them ideal for processes requiring focused and immediate sectors including automotive, packaging, plastics, textiles, food processing, and electronics rely on infrared quartz lamps for tasks such as drying, curing, forming, and surface heating. Their ability to provide uniform and controllable heat distribution enhances production speed and consistency, especially in automated or high-throughput in quartz tube design, wavelength optimization, and reflectivity enhancement is leading to more efficient, longer-lasting infrared heating solutions. Manufacturers are developing customized lamp configurations and modular systems to cater to specific heating profiles in high-precision manufacturing processes. While North America and Europe maintain significant market shares due to strong industrial bases and emphasis on energy efficiency, Asia-Pacific is emerging rapidly with growing manufacturing activities and investments in automation. The market is becoming increasingly competitive as companies emphasize value-added services, such as installation support and remote diagnostics, along with advancements in sensor integration for smart heating Takeaways - Infrared Quartz Lamp Market Widespread use in drying and curing applications is driving demand across manufacturing sectors like textiles, coatings, and adhesives. Short-wave and medium-wave variants are being tailored for materials with differing absorption characteristics, enhancing application versatility. Demand is growing for energy-efficient and quick-response heating technologies, especially in climate-sensitive production environments. Asia-Pacific is rapidly becoming a major market due to expanding industrial bases and infrastructure development across China, India, and Southeast Asia. Integration of quartz lamps in automated production lines is increasing as manufacturers seek to optimize thermal process control. North America and Europe continue to lead in product innovation, particularly in low-emission, high-durability quartz lamp solutions. Customization of lamp shapes and lengths is enabling better heat targeting in irregular or complex industrial layouts. Price volatility in raw materials such as quartz and tungsten filaments affects profit margins and procurement planning. Smart IR heating systems with feedback sensors and IoT integration are gaining traction in high-precision applications. Growing use in food and beverage processing, particularly for sterilization and drying, is diversifying market demand. Electronics and semiconductor sectors are adopting infrared quartz lamps for moisture removal and component curing processes. Increased focus on sustainability is encouraging the development of longer-life, recyclable, and RoHS-compliant lamp models. Manufacturers are offering bundled solutions that include controls, reflectors, and integration kits to streamline end-user adoption. Intense competition is pushing suppliers to invest in after-sales support, training, and global distribution capabilities. New applications in automotive repair (e.g., paint curing) and residential heating systems are contributing to expanded market reach. What You Receive Global Infrared Quartz Lamp market size and growth projections (CAGR), 2024- 2034 Impact of recent changes in geopolitical, economic, and trade policies on the demand and supply chain of Infrared Quartz Lamp. Infrared Quartz Lamp market size, share, and outlook across 5 regions and 27 countries, 2025- 2034. Infrared Quartz Lamp market size, CAGR, and Market Share of key products, applications, and end-user verticals, 2025- 2034. Short and long-term Infrared Quartz Lamp market trends, drivers, restraints, and opportunities. Porter's Five Forces analysis, Technological developments in the Infrared Quartz Lamp market, Infrared Quartz Lamp supply chain analysis. Infrared Quartz Lamp trade analysis, Infrared Quartz Lamp market price analysis, Infrared Quartz Lamp Value Chain Analysis. Profiles of 5 leading companies in the industry- overview, key strategies, financials, and products. Latest Infrared Quartz Lamp market news and developments. Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $1.31 Billion Forecasted Market Value (USD) by 2034 $2.53 Billion Compound Annual Growth Rate 7.6% Regions Covered Global Companies Featured Heraeus Noblelight GmbH GE Lighting (Savant Systems) Philips Lighting (Signify N.V.) Ushio Inc. Dr. Fischer Group Helios Quartz Group Victory Lighting Ltd. GIRIRAJ ELECTRICALS Watlow Electric Manufacturing Company Tempco Electric Heater Corporation FRICO AB IRTA Group Industrial Heater Corporation Hindalco Industries Limited SCHOTT AG Infrared Quartz Lamp Market Segmentation By Product Shortwave Mediumwave Longwave By Application Heating Lighting Cooking By End User Residential Commercial Industrial By Technology Conventional Smart By Distribution Channel Online Offline By Geography North America (USA, Canada, Mexico) Europe (Germany, UK, France, Spain, Italy, Rest of Europe) Asia-Pacific (China, India, Japan, Australia, Vietnam, Rest of APAC) The Middle East and Africa (Middle East, Africa) South and Central America (Brazil, Argentina, Rest of SCA) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Infrared Quartz Lamp Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
an hour ago
- Business
- Yahoo
Logitech International SA (LOGI) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amid ...
Net Sales Growth: 5% year over year in constant currency. Gross Margin: 42.1% for the quarter. Operating Expenses: Declined 2% year over year, representing 24.5% of net sales. Operating Cash Flow: Generated $125 million in cash from operations. Cash Balance: Ended the quarter with $1.5 billion. Shareholder Returns: $122 million returned through share repurchases. Video Collaboration Growth: 13% year over year. Personal Workspace Growth: 6% year over year, with double-digit growth in webcams and tablet accessories. Asia Pacific Growth: 15% year over year, led by China. EMEA Growth: 9% year over year. North America Performance: Declined 4% due to a pause in product shipments. Warning! GuruFocus has detected 1 Warning Sign with LOGI. Release Date: July 29, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Logitech International SA (NASDAQ:LOGI) reported a 5% year-over-year increase in net sales, demonstrating robust demand across both consumer and B2B segments. The company successfully launched nine new products, including the G522 wireless gaming headset and the Logitech Muse for the Apple Vision Pro, showcasing its commitment to innovation. Logitech's video collaboration segment grew by 13% year-over-year, driven by strong demand in North America. The Asia Pacific region saw a 15% year-over-year growth, with significant contributions from the Chinese market. Logitech maintained a strong balance sheet, ending the quarter with $1.5 billion in cash and generating $125 million in operating cash flow. Negative Points Logitech faced a 120 basis points decline in non-GAAP gross margin due to tariffs, higher promotional spend, and inventory reserve releases from the prior year. North American sales declined by 4%, primarily due to a pause in product shipments during price negotiations. The company anticipates continued uncertainty related to tariff policy, inflation, and consumer sentiment, which could impact future performance. Logitech expects a negative impact of 200 to 300 basis points from tariffs in the second quarter, partially offset by price increases. There is potential for temporary market share softening due to recent price increases, which could affect sales and consumer response. Q & A Highlights Q: What was the consumer reaction to Logitech's recent price increases, and do you plan to raise prices further to offset tariff impacts? A: Johanna Faber, CEO, explained that the positive impact of the price increase in Q1 was 50 basis points. The full implementation of the price increase was completed towards the end of the quarter, so it's too early to assess consumer reaction. The negotiations took 4 to 8 weeks, affecting in-stock levels temporarily, but inventories have since recovered, positioning Logitech well for upcoming sales periods. Q: Can you elaborate on the strength of the video collaboration business and its sustainability? A: Johanna Faber noted a 13% growth in video collaboration, driven by strong demand in North America. There might have been some advance buying due to tariffs, but overall, the business shows underlying strength with healthy inventory levels. Q: How did the B2B segment perform, and what are the financial implications of its growth? A: The B2B segment, including video conferencing and headsets, outpaced consumer demand despite a 10% price increase. Matteo Anversa, CFO, added that video conferencing is margin accretive, contributing positively to the company's overall financials. Q: What is the strategy for managing inventory and its impact on cash flow? A: Matteo Anversa stated that Logitech leveraged its strong balance sheet to pull in inventory ahead of tariffs, which helped achieve a higher gross margin. The strategy remains unchanged, aiming to protect the company and customers while maintaining strong cash flow and inventory management. Q: How does Logitech plan to achieve its 7-10% top-line growth target, and what is the timeline? A: Johanna Faber mentioned that while there are uncertainties, Logitech is pleased with current demand. The expansion into new verticals like education, healthcare, and government will take time, but core categories have shown potential to reach high single-digit growth. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
2 hours ago
- Business
- Yahoo
Drug Discovery Platforms Market Size Expected to Reach USD 635.45 Million by 2034
The global drug discovery platforms market size is calculated at USD 211.26 million in 2025 and is expected to reach around USD 635.45 million by 2034, growing at a CAGR of 13.44% for the forecasted period. Ottawa, July 30, 2025 (GLOBE NEWSWIRE) -- The global drug discovery platforms market size was valued at USD 186.24 million in 2024 and is predicted to hit around USD 635.45 million by 2034, a study published by Towards Healthcare a sister firm of Precedence Research. The growth of the market is driven by the growing investments in research and development, and integration of AI and ML with technological advancements further drives the growth of the market. Get a free sample of the Drug Discovery Platforms Market report to preview key insights and trends: Key Takeaways North America dominated the global drug discovery platforms market in 2024. Asia-Pacific is anticipated to grow at the fastest rate in the market during the forecast period. By type of display library technology, the phage display segment held a dominant presence in the market in 2024. By type of display library technology, the yeast display segment is anticipated to grow at the fastest rate in the market during the studied years. By type of molecule, the antibodies segment dominated and was observed to sustain the dominance over the forecast period. Drug Discovery Platforms Market Overview & Potential Drug discovery platforms are integrated systems designed to streamline and speed up the process of finding, developing, and refining potential drug candidates. They utilize technologies such as artificial intelligence (AI), high-throughput screening, and automation to identify promising targets and molecules. These platforms aim to enhance efficiency, cut costs, and accelerate drug development compared to traditional methods. They are transforming the pharmaceutical industry by speeding up the creation of new, effective medicines. By integrating advanced technologies and simplifying the discovery process, these platforms are set to play a vital role in future healthcare advancements. What is the Growth Potential Responsible for the Growth of the Drug Discovery Platforms Market? The global market for drug discovery platforms is growing rapidly, fueled by several key factors. These include rising rates of chronic and infectious diseases, increasing investment in pharmaceutical and biotech R&D, and technological advances like AI, machine learning, and high-throughput screening. Additionally, the focus on precision medicine and targeted therapies is expanding the market. The use of drug discovery platforms is also broadening beyond traditional pharma research to include biotech, diagnostics, and personalized medicine, further boosting growth. You can place an order or ask any questions, please feel free to contact us at sales@ What Are the Growing Trends Associated with the Drug Discovery Platforms Market? AI-powered Drug Discovery: AI is transforming drug discovery by speeding up research, increasing accuracy, and shortening development timelines. It is used in target identification, molecule design, and optimizing clinical trials. Cloud-based Platforms: Cloud computing is becoming essential in drug discovery, offering benefits like streamlined operations, lower costs, and quicker development cycles. Display Libraries: Display libraries, especially phage display, are gaining popularity for their ability to enable large-scale, high-throughput screening and increase diversity in lead discovery. Precision Medicine: Interest in precision medicine and targeted therapies is growing, with researchers aiming to develop drugs tailored to specific patient groups and disease types. What Is the Growing Challenge in the Drug Discovery Platforms Market? The drug discovery platforms market faces hurdles such as rising costs, long development times, and difficulties in accurately modeling disease mechanisms. Other issues include data privacy concerns, cybersecurity threats, and the need for skilled personnel to operate AI-based systems. These factors hinder the growth of the market and limit its expansion of the market. The government support, large patient population, growing CROs, cost effectiveness, strategic partnerships, AI and informatics, visual drug discovery services, and drug repurposing further fuel the growth and expansion of the market in the region. Get the latest insights on life science industry segmentation with our Annual Membership: Regional Analysis How Did North America Dominate the Drug Discovery Platforms Market in 2024? North America dominated the global drug discovery platforms market in 2024. The growth of the market in the region is driven by the well-established infrastructure, especially healthcare infrastructure, along with rising investment for research and development by the government, also further fuels the growth of the market in the region. The strong presence of pharmaceutical and biotechnology companies in the region also increases the demand for the market due to growing research for drug discovery and development, which further fuels the growth of the market. The supportive regulatory environment and increased research and development spending by pharmaceutical and biotech companies in the region further fuel the growth of the market in the region. The U.S. fosters drug discovery platforms market growth through strong academic-industry collaboration, advanced biotech infrastructure, and a robust intellectual property system. Government initiatives and regulatory support encourage innovation. A rich talent pool from leading universities drives research, while access to venture capital enables startups and established firms to advance novel therapies efficiently. Canada supports drug discovery through significant public funding, academic partnerships, and a collaborative research environment. Institutions emphasize translational medicine and early-stage R&D. Regulatory agencies encourage innovation with progressive frameworks. The country's multicultural population also enables diverse clinical research, strengthening Canada's role in addressing global health challenges through targeted drug development. What Made the Asia Pacific Significantly Grow in The Drug Discovery Platforms Market In 2024? Asia-Pacific is anticipated to grow at the fastest rate in the market during the forecast period. Increased government investments in pharmaceutical research and infrastructure development through government support propel the growth of the market in the region. The rising healthcare expenditure leads to greater demand for advanced healthcare solutions also increases the growth of the market. Asia Pacific is a growing and emerging hub for contract research organizations play a crucial role in outsourcing drug discovery activities by other regions' consumers, driving the growth of the market in the region. Government reforms, talent repatriation, and investment in life sciences drive China's expanding drug discovery platforms market. Research parks and biotech hubs across cities like Shanghai promote innovation. Enhanced regulatory processes and incentives for novel drug development have shifted the focus from generics to original therapeutics, boosting domestic pharmaceutical innovation. India's growth in drug discovery stems from its vast scientific workforce, cost-effective research capabilities, and strong academic institutions. Government initiatives support innovation through incubators and biotech parks. Rising collaboration between academia and industry fosters early-stage research, while improvements in regulatory frameworks encourage the development of original molecules and targeted therapies. According to Volza's Global Export data, the World shipped out 248122 Pharmaceutical shipments from November 2023 to October 2024 (TTM). These exports were handled by 7224 global exporters to 12066 buyers, showing a growth rate of 133% over the previous 12 months. Globally, India, Belgium, and the United States are the top three exporters of pharmaceuticals. India is the global leader in Pharmaceutical exports with 578683 shipments, followed closely by Belgium with 9244 shipments, and the United States in third place with 8465 shipments. Elevate your healthcare strategy with Towards Healthcare. Enhance efficiency and drive better outcomes schedule a call today: Segmental Insights By Type of Display Library Technology The phage display segment held a dominant presence in the drug discovery platforms market in 2024. The phase display is a key technology that is used in drug discovery to isolate and identify the desired molecule, especially proteins and peptides, that bind to the target molecule. The key advantages of phase displays, like high diversity, versatility, and efficiency, further increase the demand for the market. The application in drug discovery, like antibody discovery, peptide therapeutics, target validation, and vaccine development, boosts the growth of the market. The growing key therapeutic applications, like the development of therapeutic antibodies, propel the demand for the market, further contributing to the expansion of the market. The yeast display segment is anticipated to grow at the fastest rate in the drug discovery platforms market during the studied years. The growth of the market is driven by the growing applications like antibody discovery, enzyme engineering, protein-protein interaction studies, target-based drug discovery, and nanobody discovery increases the demand for the technology, which fuels the growth of the market. The growing advantages and properties offered by the technology, like quantitative analysis, compatibility with FACS, affinity maturation, high throughput screening, and eukaryotic systems, play a crucial role in further propelling the growth and expansion of the market. By Type Of Molecule The antibodies segment dominated and was observed to sustain the dominance over the forecast period. The antibodies segment holds a significant share in the drug discovery platform market, driven by the growing use of monoclonal and polyclonal antibodies in targeted therapies. These molecules are widely used in immunotherapy, oncology, and autoimmune disease treatment due to their high specificity and efficacy. Drug discovery platforms support antibody screening, engineering, and optimization, accelerating development timelines. As demand for biologics continues to rise, the adoption of advanced platforms for antibody discovery fuels market growth in this segment. Recent Developments in the Drug Discovery Platforms Market In July 2025, Elix and the Life Intelligence Consortium (LINC) announced the commercial launch of an AI-based drug discovery platform that uses federated learning across data from multiple pharmaceutical companies. This marks the first global deployment of such technology. In March 2025, Boehringer Ingelheim introduced its new comprehensive technology platform on Tuesday, aimed at streamlining data management and processes to accelerate drug development. The One Medicine Platform will replace over 20 outdated systems, creating a unified ecosystem to improve cross-functionality and operational efficiency. Top Companies and Their Contributions to the Market Company Contributions & Offerings Insilico Medicine Leverages - PandaOmics for AI-powered target/biomarker discovery, Chemistry42 for generative molecule design, and InClinico for clinical trial prediction. Has taken its lead pan-fibrotic candidate, INS018_055, from target discovery to Phase II in ~30 months. Demonstrated bioavailable CDK8 inhibitor via AI-driven Chemistry42. Evotec Offers end-to-end integrated drug discovery: target ID, screening, medicinal chemistry, biologics manufacturing, and CMC. Partners include Janssen (via TargetAlloMod), Lilly (metabolic/kidney diseases), Novartis, Novo Nordisk, Related Sciences, and more, powering multi-modality pipelines. Laboratory Corporation of America Holdings (LabCorp) Provides high-throughput pre-clinical screening, biomarker profiling, ADME/Tox, clinical trial diagnostics, and real-world evidence solutions. Integrates genomics, data analytics, and centralized labs globally to accelerate translational and clinical R&D. Atomwise Uses deep learning and structure-based AI (AtomNet) to predict protein–ligand binding, enabling virtual high-throughput screening on millions of compounds, partners with pharma and biotech to identify lead molecules for diverse therapeutic targets. Merck Owns Merck Research Labs with integrated in-house platforms including computational chemistry, high-throughput screening, and genomics. It invests in AI collaborations (e.g., with Schrödinger, Cyclica) to bolster target identification and small-molecule discovery. Pfizer Builds extensive discovery platforms—HTS, structural biology, chemoinformatics, AI/ML modeling, and phenotypic screening. Active in AI drug discovery partnerships (e.g., XtalPi, DeepMind), and open science efforts for protein structure and drug-target mapping. Exscientia plc Pioneers AI-driven end-to-end drug design, advancing candidate molecules into clinical trials faster via Centaur Chemist. Publishes human-dose candidates from AI design, with strategic pharma partnerships and a pipeline in immuno-oncology and cardiometabolic diseases. Thermo Fisher Scientific Supplies essential platforms: high-throughput screening systems, mass spectrometry, protein analysis, cell-based assays, informatics software, and reagent kits. Supports discovery across small molecules, biologics, and cell therapies via integrated hardware and software solutions. Recursion Pharmaceuticals Combines automated biology (cell imaging) with AI/ML to rapidly characterize disease models and drug effects. Progressed eight AI-designed drug candidates (REC-3565, REC-994, etc.) into clinical trials. Offers Recursion OS, enabling biology-first target discovery. Eli Lilly and Company Maintains Lilly Research Labs with integrated capabilities: high-throughput screening, structural biology, computational chemistry, and translational biomarkers. Partners with AI-first firms (e.g., with Evotec, Insilico) to accelerate novel therapeutic target discovery and drug design. Browse More Insights of Global Drug Discovery & Development The GLP-1 drugs market is witnessing rapid momentum worldwide, with expectations of generating substantial revenue potentially in the hundreds of millions between 2025 and 2034. The global immuno-oncology drugs market is on a high-growth trajectory. Valued at US$ 94 billion in 2024, it is projected to reach US$ 109.39 billion in 2025 and soar to approximately US$ 421.27 billion by 2034, growing at a CAGR of 16.34% over the forecast period. The U.S. drug screening market is steadily growing. From US$ 2.70 billion in 2024 to US$ 2.79 billion in 2025, it's expected to reach US$ 3.84 billion by 2034, expanding at a CAGR of 3.64%. The computer-aided drug design (CADD) market is gaining traction globally, with anticipated revenues climbing into the hundreds of millions over the next decade. The drug discovery SaaS platforms market is evolving fast, expected to generate significant revenue between 2025 and 2034 as digital transformation accelerates across pharma R&D. The drug discovery as a service market is expanding rapidly from US$ 21.3 billion in 2024 to US$ 24.32 billion in 2025, and is forecasted to reach US$ 79.82 billion by 2034, growing at a CAGR of 14.17%. The generative AI in drug discovery market is making waves. Valued at US$ 250 million in 2024, it's set to grow to US$ 318.55 million in 2025, and nearly US$ 2.85 billion by 2034, posting an impressive CAGR of 27.42%. The machine learning in drug discovery market is experiencing a notable surge, with revenues expected to reach several hundred million dollars by 2034, reflecting growing adoption across the pharmaceutical value chain. Similarly, the AI and ML in drug development market is rapidly expanding worldwide, with strong potential for multimillion-dollar revenues throughout the forecast period. The sterile drug product testing market is on a growth path driven by rising production of biologics and injectable drugs, making it a key segment to watch from 2024 to 2034. Drug Discovery Platforms Market Key Players Insilico Medicine Evotec Laboratory Corporation of America Holdings Atomwise Merk Pfizer Exscientia plc Thermo Fisher Recursion Pharmaceuticals Eli Lilly and Company Roche Segments Covered in The Report By Type of Display Library Technology Phage display library Yeast display Other By Type of Molecule Antibodies Peptides Other By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Access the complete Drug Discovery Platforms Market report for in-depth analysis, forecasts, and strategic recommendations: You can place an order or ask any questions, please feel free to contact us at sales@ Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire Find us on social platforms: LinkedIn | Twitter | InstagramSign in to access your portfolio
